Vigil Neuroscience (VIGL) News Today $2.34 -0.03 (-1.10%) As of 01:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VIGL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period HC Wainwright Expects Higher Earnings for Vigil NeuroscienceVigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - HC Wainwright raised their Q2 2025 earnings per share (EPS) estimates for shares of Vigil Neuroscience in a research note issued on Thursday, May 8th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings of ($0.48May 13 at 1:13 AM | marketbeat.comQ2 EPS Estimate for Vigil Neuroscience Increased by AnalystVigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Investment analysts at Wedbush increased their Q2 2025 earnings per share estimates for Vigil Neuroscience in a report issued on Wednesday, May 7th. Wedbush analyst L. Chico now forecasts that the company will earn ($0.39) per share for the qMay 13 at 1:13 AM | marketbeat.comHC Wainwright Issues Optimistic Forecast for VIGL EarningsMay 13 at 1:04 AM | americanbankingnews.comWedbush Lifts Earnings Estimates for Vigil NeuroscienceMay 13 at 1:04 AM | americanbankingnews.comVigil Neuroscience, Inc.: Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business UpdatesMay 7, 2025 | finanznachrichten.deWedbush Reaffirms Outperform Rating for Vigil Neuroscience (NASDAQ:VIGL)Wedbush restated an "outperform" rating and issued a $13.00 price target on shares of Vigil Neuroscience in a report on Monday.May 7, 2025 | marketbeat.comVigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business UpdatesMay 7, 2025 | globenewswire.comMarshall Wace LLP Acquires 122,853 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)Marshall Wace LLP raised its stake in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 85.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 266,895 shares of the company's stock after acquiring an additional 122,853 shares during the periodMay 6, 2025 | marketbeat.comVigil Neuroscience Inc.May 6, 2025 | barrons.comBoothbay Fund Management LLC Makes New $249,000 Investment in Vigil Neuroscience, Inc. (NASDAQ:VIGL)Boothbay Fund Management LLC purchased a new stake in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 146,750 shares of the company's stock, valued at approMay 5, 2025 | marketbeat.comRenaissance Technologies LLC Has $624,000 Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)Renaissance Technologies LLC lifted its position in Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 698.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 367,300 shares of the company's stock after buying an additioMay 5, 2025 | marketbeat.com683 Capital Management LLC Purchases 180,420 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)683 Capital Management LLC increased its stake in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 14.8% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,400,000 shares oMay 4, 2025 | marketbeat.comVigil Neuroscience (VIGL) Projected to Post Earnings on TuesdayVigil Neuroscience (NASDAQ:VIGL) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-vigil-neuroscience-inc-stock/)May 1, 2025 | marketbeat.comVigil Neuroscience Stock Short Interest Report | NASDAQ:VIGL | BenzingaApril 30, 2025 | benzinga.comVigil Neuroscience (NASDAQ:VIGL) Upgraded by William Blair to "Strong-Buy" RatingWilliam Blair upgraded shares of Vigil Neuroscience to a "strong-buy" rating in a research note on Thursday.April 28, 2025 | marketbeat.comBlair William & Co. IL Buys Shares of 323,900 Vigil Neuroscience, Inc. (NASDAQ:VIGL)Blair William & Co. IL purchased a new stake in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 323,900 shares of the company's stock,April 6, 2025 | marketbeat.comVigil presents data on oral small molecule program including VG-3927April 3, 2025 | markets.businessinsider.comWilliam Blair Remains a Buy on Vigil Neuroscience Inc (VIGL)April 3, 2025 | markets.businessinsider.comVigil Neuroscience Presents Data on its Small Molecule TREM2 Agonist VG-3927 in Two Oral Presentations at AD/PD™ 2025 International ConferenceApril 2, 2025 | globenewswire.comVigil Neuroscience Reports 2024 Results and Clinical ProgressApril 2, 2025 | tipranks.comVigil Neuroscience files to sell 5.38M shares of common stock for holdersApril 1, 2025 | markets.businessinsider.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Sees Large Drop in Short InterestVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) saw a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 419,400 shares, a decrease of 25.6% from the February 28th total of 564,000 shares. Approximately 1.9% of the company's stock are short sold. Based on an average daily trading volume, of 1,010,000 shares, the short-interest ratio is presently 0.4 days.March 31, 2025 | marketbeat.comVigil Neuroscience (VIGL) to Release Earnings on TuesdayVigil Neuroscience (NASDAQ:VIGL) will be releasing earnings before the market opens on Tuesday, March 25, Financial Modeling Prep reports.March 18, 2025 | marketbeat.comFY2029 Earnings Forecast for VIGL Issued By WedbushVigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Research analysts at Wedbush issued their FY2029 EPS estimates for shares of Vigil Neuroscience in a note issued to investors on Thursday, March 13th. Wedbush analyst L. Chico anticipates that the company will earn $1.40 per share for the yeaMarch 17, 2025 | marketbeat.comQ1 Earnings Estimate for VIGL Issued By William BlairVigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) - Research analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for Vigil Neuroscience in a research report issued on Thursday, March 13th. William Blair analyst S. Schram forecasts that the company will earn $0.49March 17, 2025 | marketbeat.comWedbush Issues Pessimistic Forecast for Vigil Neuroscience (NASDAQ:VIGL) Stock PriceWedbush cut their target price on shares of Vigil Neuroscience from $24.00 to $13.00 and set an "outperform" rating on the stock in a report on Friday.March 15, 2025 | marketbeat.comVigil Neuroscience (NASDAQ:VIGL) Given New $14.00 Price Target at HC WainwrightHC Wainwright cut their target price on shares of Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating for the company in a report on Friday.March 15, 2025 | marketbeat.comVigil Neuroscience price target lowered to $14 from $17 at H.C. WainwrightMarch 14, 2025 | markets.businessinsider.comVigil Neuroscience price target lowered to $13 from $24 at WedbushMarch 14, 2025 | markets.businessinsider.comVigil Neuroscience (NASDAQ:VIGL) Announces Earnings ResultsVigil Neuroscience (NASDAQ:VIGL - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.08).March 14, 2025 | marketbeat.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest UpdateVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) saw a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 564,000 shares, a decline of 44.7% from the February 13th total of 1,020,000 shares. Approximately 2.9% of the company's stock are short sold. Based on an average daily trading volume, of 1,030,000 shares, the short-interest ratio is presently 0.5 days.March 14, 2025 | marketbeat.comVigil Neuroscience Faces Market Risks from Preferred Stock Issuance and Potential Share DilutionMarch 14, 2025 | tipranks.comVigil Neuroscience, Inc.: Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business UpdatesMarch 13, 2025 | finanznachrichten.deVigil Neuroscience reports Q4 EPS (57c), consensus (47c)March 13, 2025 | markets.businessinsider.comVigil Neuroscience sees cash runway into 2026March 13, 2025 | markets.businessinsider.comVigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business UpdatesMarch 13, 2025 | globenewswire.comVigil Neuroscience to Present at the Stifel 2025 Virtual CNS ForumMarch 11, 2025 | globenewswire.comVigil Neuroscience, Inc. (NASDAQ:VIGL) Short Interest Down 43.6% in FebruaryVigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) saw a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 1,020,000 shares, a drop of 43.6% from the January 31st total of 1,810,000 shares. Based on an average daily trading volume, of 1,060,000 shares, the short-interest ratio is presently 1.0 days. Approximately 5.2% of the shares of the company are sold short.March 2, 2025 | marketbeat.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL)February 20, 2025 | prnewswire.comabrdn plc Buys 293,461 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)abrdn plc increased its stake in Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 124.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 528,472 shares of the company's stock after buying an additional 293,461 sharFebruary 11, 2025 | marketbeat.comVigil Neuroscience Inc (VIGL) Receives a Buy from Stifel NicolausFebruary 10, 2025 | markets.businessinsider.comVigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech ConferenceJanuary 30, 2025 | globenewswire.comVigil Neuroscience reports data from Phase 1 trial on VG-3927January 24, 2025 | markets.businessinsider.comVigil Neuroscience (NASDAQ:VIGL) Receives "Buy" Rating from GuggenheimGuggenheim reiterated a "buy" rating on shares of Vigil Neuroscience in a research report on Friday.January 24, 2025 | marketbeat.comVigil Neuroscience: Now A 'Hold' Based On Two New Pipeline DevelopmentsJanuary 24, 2025 | seekingalpha.comVigil Neuroscience shares rise on positive Alzheimer's trial dataJanuary 23, 2025 | msn.comVigil Neuroscience’s VG-3927: Promising Phase 1 Results and Strategic Positioning for Phase 2January 23, 2025 | markets.businessinsider.comOptimistic Outlook for Vigil Neuroscience Inc: Promising Phase 1 Results and Strategic Partnership Potential for VG-3927January 23, 2025 | markets.businessinsider.comVigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s DiseaseJanuary 23, 2025 | finance.yahoo.comVigil Neuroscience gains as Alzheimer’s drug reaches mid-stage trialJanuary 23, 2025 | msn.com Get Vigil Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address VIGL Media Mentions By Week VIGL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIGL News Sentiment▼1.050.79▲Average Medical News Sentiment VIGL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIGL Articles This Week▼172▲VIGL Articles Average Week Get Vigil Neuroscience News Delivered to You Automatically Sign up to receive the latest news and ratings for VIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CGEM News Today ETON News Today ALT News Today SANA News Today MGTX News Today MAZE News Today SIGA News Today ZVRA News Today SAGE News Today AMLX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIGL) was last updated on 5/15/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredSilver Demand Is Soaring-Supply Can't Keep UpSilver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. I...i2i Marketing Group, LLC | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vigil Neuroscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vigil Neuroscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VIGL Stock Free VIGL Stock Alerts